Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBvB Sequential Treatment in Newly Diagnosed PTLD
NCT04138875Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in Post-Transplant Lymphoproliferative Disorder (PTLD) (2 arms), sponsored by Yale University. Primary endpoints: Overall Response Rate up to 84 days and Progression Free Survival up to 84 days. Planned start Jan 2022; status: withdrawn.
02
Drugs
brentuximab vedotin
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT04138875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138875.